Figure 5
From: Preclinical efficacy of CIGB-300, an anti-CK2 peptide, on breast cancer metastasic colonization
CIGB-300 treatment inhibits breast cancer metastasis to lung. (A) Tail vein experimental metastasis: F3II cells were injected in the lateral tail vein of mice. Mice were treated with CIGB-300 at a 10 mg/kg i.v. dose, during five consecutive days, and sacrificed at day 21. The number of lung nodules per animal is represented in the graph. Data are expressed as scatter dot plot and median (n = 9–10 per experimental group). **p < 0.01, Unpaired Mann–Whitney test. (B) Experimental metastasis after incomplete surgical resection of primary tumor: F3II cells were injected subcutaneously in the right flank of BALB/c mice to generate primary tumors. On day 35 after tumor cell inoculation, an incomplete surgical resection of the tumor was performed. Immediately after surgery mice were treated daily with 10 mg/kg i.v. dose of CIGB-300 five consecutive days after surgery, and five consecutive days after day 10 post-surgery. On day 70 animals were sacrificed. n = 7–8 per experimental group. *p < 0.05 and ***p < 0.001, **p < 0.01, Unpaired Mann–Whitney test.
